UCB today announced significant positive results from the first study to evaluate the efficacy and safety of CIMZIA™ (certolizumab pegol, CDP870), a new type of anti-tumour necrosis factor (anti-TNF) therapy, in the treatment of patients with moderate to severe psoriasis.
